HARBIN, China, July 10 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. (“China Sky One Medical” or “the Company”) , a leading fully integrated pharmaceutical company producing external use, over- the-counter drugs in the People’s Republic of China (“PRC”), announced today that it has 11 new drugs that have entered into clinical trials, including seven administered by injection.
China Sky One has a history of successfully producing external use drugs and has now set its sights on developing drugs for injection, a market where it sees a great deal of potential. Out of the 11 new drugs currently undergoing clinical trials that are listed below, seven of them are administered by injection:
“We are very excited about our pipeline of newly developed drugs,” said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical, Inc. “They are now in clinical trials and we are confident that they can expand our market share and increase profitability going forward. Our move into the injectable drug delivery market represents a strong opportunity for future growth since the traditional injection is still a dominant delivery method. The testing for these drugs needs about six month to complete and may submit them to the SFDA for approval in the beginning of 2009.”
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (“TDR”) and Harbin First Bio- Engineering Company Limited (“First”), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
CONTACT: Company Contact: China Sky One Medical, Inc., Ms. Yanwei Zhang,
Board Secretary, +86-451-53994064 or cntiandiren@yahoo.com.cn; Investor
Relations Contact: CCG Elite Investor Relations, Mr. Crocker Coulson,
President, +1-646-213-1915, or crocker.coulson@ccgir.com; Mr. Richard
Micchelli, Financial Writer, +1-646-454-4516, or
richard.micchelli@ccgir.com
Web site: http://www.skyonemedical.com/
http://www.ccgelite.com/
